Lv4
460 积分 2024-01-05 加入
Outcomes According to Coronary Disease Complexity and Optimal Thresholds to Guide Revascularization Approach
10小时前
待确认
Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention
1个月前
已完结
Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point–Blinded, Noninferiority Trial
1个月前
已完结
Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point–Blinded, Noninferiority Trial
1个月前
已完结
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial
2个月前
已完结
Molecular insights into human phosphatidylserine synthase 1 reveal its inhibition promotes LDL uptake
3个月前
已完结
One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes
5个月前
已关闭
Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial
5个月前
已完结
Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial
5个月前
已完结
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial
6个月前
已完结
皖公网安备34019202002308
